(原标题:信达生物制药(01801.HK)2026年2月股份变动月报)金吾财讯|信达生物制药(01801.HK)于2026年3月5日提交了2026年2月的股份变动月报表。报告显示,公司在该月内法定/注册股本及已发行股份均未发生变动,法定/注册股本总额保持在50,000美元,已发行普通股总数为1,735,186,039股。 在股份期权方面,公司的首次公开发售前股份奖励计划、首次公开发售后雇员持股计划...
Source Link(原标题:信达生物制药(01801.HK)2026年2月股份变动月报)金吾财讯|信达生物制药(01801.HK)于2026年3月5日提交了2026年2月的股份变动月报表。报告显示,公司在该月内法定/注册股本及已发行股份均未发生变动,法定/注册股本总额保持在50,000美元,已发行普通股总数为1,735,186,039股。 在股份期权方面,公司的首次公开发售前股份奖励计划、首次公开发售后雇员持股计划...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.